Compare Bioavailability of BMS-986089 After Subcutaneous Injection

  • Healthy Volunteers
Trial Status:


This trial runs in
  • Cypress
Trial Identifier:

NCT03100630 WP40225 CN001-023

      Show trial locations

      The source of the below information is the publicly available website It has been summarised and edited into simpler language.

      The below information is taken directly from the publicly available website within a week of any updates, and has not been edited.

      Results Disclaimer

      Trial Summary

      Randomized study in healthy men and women. Assess the similarity of RO7239361 when injected into the arm, thigh, or the stomach. Collect data on safety of RO7239361.

      Hoffmann-La Roche Sponsor
      Phase 1 Phase
      NCT03100630 , CN001-023 , WP40225 Trial Identifier
      RO7239361 Treatments
      Healthy Condition
      Official Title

      An Open-label, Randomized, Parallel-group, Single Dose Study to Compare the Bioavailability of Subcutaneous Injections in the Arm, Thigh, and Abdomen and to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of RO7239361 in Healthy Participants

      Eligibility Criteria

      All Gender
      ≥ 18 Years & ≤ 55 Years Age
      Accepts Healthy Volunteers Healthy Volunteers
      Inclusion Criteria
      • Healthy participant as determined by no significant deviations in normal medical and surgical history and assessments
      • Body Mass Index 18 kg/m2 to 32 kg/m2
      • females must be of non-childbearing potential
      Exclusion Criteria
      • tattoos or other skin findings on any of the potential injection sites
      • history of chronic muscle pain within 30 days prior to study treatment
      • prior history of IgG1 therapy

      Other protocol defined inclusion and exclusion criteria apply

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now